Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000624520 | SCV000741059 | likely pathogenic | Inborn genetic diseases | 2015-11-09 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002532827 | SCV003016381 | likely pathogenic | Spastic paraplegia | 2023-04-24 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts a region of the AP4S1 protein in which other variant(s) (p.Leu6Pro) have been observed in individuals with AP4S1-related conditions (PMID: 32979048). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 520786). Disruption of the initiator codon has been observed in individual(s) with clinical features of hereditary spastic paraplegia (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change affects the initiator methionine of the AP4S1 mRNA. The next in-frame methionine is located at codon 7. |